infection

Biotech

X4 scores a phase 3 win for immune deficiency disorder drug

Four months after laying off staff, X4 says its WHIM syndrome therapy improved white blood cell counts in patients during a phase 3 trial.
Annalee Armstrong Nov 30, 2022 10:45am

Could a single pill outsmart a tumor's resistance mechanisms?

Mar 29, 2021 10:00am

Gilead snaps ups German virology biotech MYR

Dec 10, 2020 8:55am

Takeda's maribavir hits phase 3 goal

Dec 4, 2020 8:47am

Finch nets $90M to push C. diff microbiome med toward FDA filing

Sep 17, 2020 7:00am

Lumen hires Spigarelli to lead infectious disease work

Sep 10, 2020 8:35am